Evidence map›Paper›PMID 39282894›Full record

ArticleNanotoxicology2024

Immunological properties of silica nanoparticles: a structure-activity relationship study.

Jason William Grunberger, Marina A Dobrovolskaia, Hamidreza Ghandehari

Abstract read
In one paragraph

Article in Nanotoxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Effects of silica nanoparticles with varied physicochemical properties on the survival and functionality of saturated macrophages.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jason William GrunbergerUtah Center for Nanomedicine, Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, USA.
Marina A DobrovolskaiaNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD, USA.
Hamidreza GhandehariUtah Center for Nanomedicine, Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, USA.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
BIOLOGICAL FATE AND BIOCOMPATIBILITY OF SILICA-BASED NANOCONSTRUCTSR01ES024681 · NIEHS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Hamid Ghandehari · 2014 to 2026
$4.1M
NCI NIH HHS 75N91019D00024NIEHS NIH HHS R01 ES024681
6 · The paper itself

Abstract

Silica nanoparticles are increasingly considered for drug delivery applications. These applications require an understanding of their biocompatibility, including their interactions with the immune system. However, systematic studies for silica nanoparticle immunological safety profiles are lacking. To fill this gap, we conducted an

Indexed as

NanoparticlesSilicon DioxideCell ProliferationComplement ActivationHemolysisHumansParticle SizePhagocytosisPlatelet AggregationStructure-Activity RelationshipSilicon Dioxidedrug deliveryhematological compatibilityimmunotoxicitySilica nanoparticles

Identifiers

PMID39282894
PMCPMC11581911

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.